Riddell Michael C, Lewis Dana M, Turner Lauren V, Lal Rayhan A, Shahid Arsalan, Zaharieva Dessi P
School of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, Canada.
OpenAPS, Seattle, WA, USA.
J Diabetes Sci Technol. 2024 Aug 14:19322968241267820. doi: 10.1177/19322968241267820.
Automated insulin delivery (AID) systems enhance glucose management by lowering mean glucose level, reducing hyperglycemia, and minimizing hypoglycemia. One feature of most AID systems is that they allow the user to view "insulin on board" (IOB) to help confirm a recent bolus and limit insulin stacking. This metric, along with viewing glucose concentrations from a continuous glucose monitoring system, helps the user understand bolus insulin action and the future "threat" of hypoglycemia. However, the current presentation of IOB in AID systems can be misleading, as it does not reflect true insulin action or automatic, dynamic insulin adjustments. This commentary examines the evolution of IOB from a bolus-specific metric to its contemporary use in AID systems, highlighting its limitations in capturing real-time insulin modulation during varying physiological states.
自动胰岛素给药(AID)系统通过降低平均血糖水平、减少高血糖和最小化低血糖来改善血糖管理。大多数AID系统的一个特点是,它们允许用户查看“体内胰岛素量”(IOB),以帮助确认近期的大剂量胰岛素注射并限制胰岛素叠加。这一指标,连同从连续血糖监测系统查看血糖浓度,有助于用户了解大剂量胰岛素的作用以及未来低血糖的“威胁”。然而,AID系统中目前IOB的呈现方式可能会产生误导,因为它不能反映真正的胰岛素作用或自动、动态的胰岛素调整。本评论探讨了IOB从一个特定于大剂量胰岛素注射的指标到其在AID系统中的当代应用的演变,强调了其在捕捉不同生理状态下实时胰岛素调节方面的局限性。